China's Fosun plans plant to make BioNTech's Covid-19 vaccine -Caixin
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SATURDAY, MAY 21, 2022
SATURDAY, MAY 21, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
China's Fosun plans plant to make BioNTech's Covid-19 vaccine -Caixin

Coronavirus chronicle

Reuters
31 December, 2020, 04:45 pm
Last modified: 31 December, 2020, 04:49 pm

Related News

  • Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children
  • Pfizer/BioNTech Covid-19 vaccine effectiveness drops after 6 months, study shows
  • US FDA grants full approval to Pfizer-BioNTech Covid-19 vaccine
  • Pfizer, BioNtech submit data to FDA for Covid-19 vaccine booster authorisation
  • BioNTech says vaccine repeats beat devising new one for now

China's Fosun plans plant to make BioNTech's Covid-19 vaccine -Caixin

Caixin’s latest version of the story dropped a paragraph saying that Fosun plans to set up a joint venture with BioNTech

Reuters
31 December, 2020, 04:45 pm
Last modified: 31 December, 2020, 04:49 pm
"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected
"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin, chief executive of the company.  Photo: Collected

Shanghai Fosun Pharmaceutical Group is planning a facility in China to produce the Covid-19 vaccine developed by Germany's BioNTech, financial magazine Caixin reported on Wednesday.

The first phase of the China-based manufacturing facility will have production capacity of 200 million doses, Caixin said, citing people familiar with the matter. It did not specify how long it would take to produce that many doses.

Caixin's latest version of the story dropped a paragraph saying that Fosun plans to set up a joint venture with BioNTech.

In a written response to a Reuters request for comment, a BioNTech representative said the detailed supply arrangement will be subject to further negotiation and agreement between the companies.

"BioNTech and Fosun Pharma are communicating about these possible forms," the representative added.

Fosun Pharma had said it aims to move from importing finished vaccine from the German company to conducting some filling procedures on its own, using imported bulk ingredients and then eventually making vaccines from scratch, though it has not announced a specific timeline.

Fosun this month said it will buy at least 100 million doses of vaccine from BioNTech for use in mainland China next year if the vaccine receives regulatory approval in the country.

Shanghai Fosun Pharmaceutical Group / BionTech Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    Tough conditions get in way of Indian wheat import
  • Zahid Hussain/TBS Sketch
    Our problematic macroeconomic duo
  • US growth seen outpacing China’s for first time since 1976
    US growth seen outpacing China’s for first time since 1976

MOST VIEWED

  • A worker disinfects a vehicle carrying medical oxygen, in Pyongyang. Photo: Collected
    North Korea using traditional medicine to fight Covid
  • Ryu Yong Chol, an official at North Korea's state emergency epidemic prevention headquarters, speaks during a daily coronavirus program on state-run television KRT, in this still image obtained from KRT footage released on May 20, 2022. REUTERS TV/KRT via REUTERS
    North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Shanghai detects new infections after five days of 'zero Covid'
  • Volunteers carry out temperature screening during an anti-virus campaign in Pyongyang, North Korea in this image released by North Korea's Korean Central News Agency (KCNA) on March 4, 2020. KCNA via REUTERS/File Photo
    North Korea hails 'good results' on Covid as fever cases pass 2 million
  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial

Related News

  • Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children
  • Pfizer/BioNTech Covid-19 vaccine effectiveness drops after 6 months, study shows
  • US FDA grants full approval to Pfizer-BioNTech Covid-19 vaccine
  • Pfizer, BioNtech submit data to FDA for Covid-19 vaccine booster authorisation
  • BioNTech says vaccine repeats beat devising new one for now

Features

Mohammad (Mejbah) Mejbahuddin, Former Senior Secretary, Economic Relations Division (ERD), Ministry of Finance, Government of Bangladesh. TBS Sketch

‘No project is being delayed too long at the moment’

15h | Panorama
Dr Shamsul Hoque, Professor, Civil Engineering, BUET. TBS Sketch

‘Planning commission only in the name, there are no planners’ 

15h | Panorama
Masrur Reaz. TBS Sketch

‘To ensure accountability, contract financing should be based on ‘performance based payments’

15h | Panorama
Professor Mustafizur Rahman. Illustration: TBS

Project delays and escalating costs are driven by frequent revisions and lack of good governance

18h | Panorama

More Videos from TBS

Ways to retain body fragrance

Ways to retain body fragrance

16h | Videos
Gazipur restaurant that serves 150 food items

Gazipur restaurant that serves 150 food items

20h | Videos
How to prepare for a job

How to prepare for a job

21h | Videos
Putin's strategies to face Nato

Putin's strategies to face Nato

1d | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

6
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab